drugset / Trial / NCT01847807

The Organ Protection of Astragalus in Subjects With Metabolic Syndrome

NCT01847807

Phase 3 Completed 210 enrolled LanZhou University
RandomizedParallel-groupSingle-blindTreatment

Summary

Metabolic syndrome have the damages on tissues and organs in heart、kindey and vessels. In this study, prospective randomized, controlled, parallel designed ,different doses of Astragalus Mongolia, Gansu Longxi produce treat on the MS patients, and then use real-time quantitative PCR and Western Blotting to detect the index of oxidative stress 、angiotensin-converting enzyme 2 mRNA expression and proteins.

Timeline

Start
2011-01
Primary completion
2015-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Astragalus Traditional medicine (herbal / TCM) 5 g
Comparator Astragalus Traditional medicine (herbal / TCM) 10 g

Indications